JimmyToowong Posted July 31, 2011 Share Posted July 31, 2011 BJU Int. 2010 Jan;105(1):42-8. Epub 2009 Jun 10. Body mass index is not a prognostic marker for prostate-specific antigen failure and survival in Dutch men treated with brachytherapy. van Roermund JG, Hinnen KA, Battermann JJ, Witjes JA, Bosch JL, Kiemeney LA, van Vulpen M. Department of Urology, University Medical Center Utrecht, University Medical Center Utrecht, Utrecht, The Netherlands. j.g.h.vanroermund@umcutrecht.nl Abstract OBJECTIVE: To examine the relationship between body mass index (BMI) and biochemical recurrence (BCR), cancer-specific (CSS) and overall survival (OS) in men treated with permanent prostate brachytherapy (PPB), as there is limited information on the affect of obesity on treatment outcomes for prostate cancer. PATIENTS AND METHODS: In all, 1530 patients with clinically localized prostate cancer who underwent PPB were studied. Clinical and pathological data were retrospectively obtained from medical records. The BMI was classified as normal (< 25 kg/m(2)), overweight (25-30 kg/m(2)) and obese (> or = 30 kg/m(2)). BCR was defined as a rise in PSA levels of > or = 2 ng/mL after the nadir had been reached. The cause of death was determined for each deceased patient. Patients with metastatic prostate cancer who died of any cause were classified as prostate cancer deaths. RESULTS In all, 617 (40%) patients were classified as having a normal weight, 754 (49%) overweight and 159 (10%) were obese. The Kaplan-Meier 8-year risk of BCR (95% confidence interval) was 33.3% (27.2-39.4), 29.2% (23.5-34.9) and 29.3% (12.4-46.2) for patients with a BMI of < 25 kg/m(2), 25-30 kg/m(2) and > or = 30 kg/m(2), respectively. The 8-year CSS was 88.2% (83.1-93.3), 88.6% (83.7-93.5) and 90.6% (79.9-101.4) and the 8-year OS was 70.1% (63.6-76.6), 72.9% (66.6-79.2) and 81.8% (69.3-94.3) for these three groups, respectively. Multivariate proportional hazard regression analyses of BMI and established prognostic factors for BCR confirmed the absence of any prognostic value of BMI on BCR, CSS and OS. CONCLUSIONS: BMI did not appear to have any prognostic value for BCR, CCS or OS in patients with clinically localized prostate cancer treated with PPB. PMID: 19519759 Forum: Primary hormone therapy Title: With brachy, PMI is not predictive This extract can be found on http://PubMed.com, and is in the public domain. On PubMed.com there will be a link to the full paper (often $30, sometimes free). Any highlighting (except the title) is not by the author, but by Jim Marshall. Jim is not a doctor. This page was found on the Advanced Prostate Cancer Community for Australian men at http://advancedprost...lia.ipbhost.com. The link is hard to remember. An easier way to find it is to go to JimJimJimJim.com and click on Prostate. That's the word Jim four times, no spaces, followed by .com. If you need other help - to perhaps find someone to talk to or a local support group: Click on the Contact Jim button at http://JimJimJimJim.com. Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.